【英語タイトル】Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030
	・商品コード：BT 6939 ・発行会社（調査会社）：MarketsandMarkets ・発行日：2025年5月 ・ページ数：約300 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後1営業日） ・調査対象地域：グローバル ・産業分野：医療

The global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million in 2025, at a CAGR of 17.5% during the forecast period. The expansion of the exosome research market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as potential biomarkers and their capacity to facilitate targeted therapeutic delivery, are uniquely positioned to address the increasing demand for advanced disease diagnostics and treatment modalities.

“The kits & reagents segment is expected to grow at the highest CAGR during the study period.”

As academic institutions, biotechnology companies, and diagnostic developers delve deeper into the multifaceted roles of exosomes in disease diagnostics and therapeutic interventions, there has been a notable increase in the demand for standardized, user-friendly kits & reagents. These specialized tools play a crucial role in simplifying and expediting the workflows associated with exosome isolation, purification, labeling, and downstream analysis. Exosomes, nano-sized vesicles secreted by cells, have emerged as significant biomarkers in various diseases, necessitating precise handling and analysis. The standardization offered by commercially available kits helps ensure that researchers can perform these tasks with consistency and reliability, which is vital in both translational research and preclinical development. In particular, reproducibility is critical in scientific research; utilizing validated kits ensures consistent protocols that minimize variability and enhance overall research outcomes. This reliability is particularly pertinent in biomarker discovery and liquid biopsy research, where the identification of accurate biomarkers is paramount for early disease detection and monitoring. With the growing interest in exosome-based diagnostics—especially within oncology for cancer detection and neurodegenerative diseases like Alzheimer’s and Parkinson’s—laboratories are increasingly opting for ready-to-use reagent systems. These systems facilitate sample preparation, RNA and DNA extraction, and comprehensive cargo profiling, thereby supporting a range of downstream molecular applications. The integration of such standardized tools not only streamlines the research process but also enhances the quality of data generated, ultimately contributing to the advancement of exosome research in clinical settings. As the landscape of diagnostics continues to evolve, the role of such reliable and efficient kits will become even more pronounced, paving the way for breakthroughs in personalized medicine and targeted therapies.

“North America is expected to grow at the highest CAGR in the global exosome research market from 2025 to 2030.”

North America maintains its leading position in the global exosome research market, primarily due to substantial government investment and support mechanisms. Key organizations such as the National Institutes of Health (NIH) in the United States are pivotal, channeling significant funding into biomedical research, specifically targeting projects centered on exosomes. This financial endorsement empowers researchers to explore novel applications of exosomes in both diagnostics and therapeutics. For example, in June 2024, the National Heart, Lung, and Blood Institute (NHLBI) renewed a USD 12 million Program Project Grant (PPG) to support researchers at the Lewis Katz School of Medicine at Temple University. Their investigation focuses on heart cell-derived exosomes and their involvement in cardiac injury and repair processes. This funding facilitates a deeper understanding of the mechanisms by which exosomes contribute to myocardial tissue regeneration, potentially leading to groundbreaking therapeutic strategies. Likewise, in August 2023, the National Cancer Institute (NCI) allocated USD 2.5 million to the Sylvester Comprehensive Cancer Center to advance research on exosome-based biomarkers for prostate cancer detection through urine and blood assays. Such robust government backing not only propels scientific exploration but also fosters collaboration between academic institutions and industry, thereby cultivating a dynamic research ecosystem. This well-capitalized environment accelerates innovation and reinforces North America’s status as a frontrunner in exosome research. As a result, the region continues to draw in investments and talent, driving ongoing growth within the exosome research sector.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side-70% and Demand Side-30%
• By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
• By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%
List of Key Companies Profiled in the Report:

Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), Danaher Corporation (US), Capricor Therapeutics(US), Lonza (Switzerland), QIAGEN (Germany), Creative Medical Technologies Holdings, Inc. (US), System Biosciences, LLC (US), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), Creative Biolabs (US), Nanofcm (UK), Izon Science (UK), and Malvern Panalytical (UK).

Research Coverage:

This research report categorizes the exosome research market by offering [kits & reagents (antibodies, isolation, purification, quantitation kits, reagents, and other kits & reagents), instruments, and services], indication [cancer indication (lung cancer, breast cancer, prostate cancer, colorectal cancer, other cancers), neurodegenerative diseases, cardiovascular diseases, infectious diseases, and other indications], by application [biomarkers, vaccine development, tissue regeneration, and other applications], by manufacturing services [stem cell-derived exosome manufacturing services, dendritic cell-derived exosome manufacturing services, and other manufacturing services] by end user [academic & research institutes, pharmaceutical & biotechnological companies, and hospitals & clinical laboratories] and by region [North America, Europe, Asia Pacific, Latin America, Middle East & Africa].

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the exosome research market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the Exosome Research market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (increasing investment in pharmaceutical & life sciences research, rising cancer prevalence, and increasing interest in exosome-based procedures), restraints (technical complexity of exosome isolation, and regulatory uncertainty in exosome research), opportunities (rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, and increasing demand for personalized medicines), and Challenges (lack of gold standard protocols for exosome development and production and limited understanding of cargo loading).
• Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the exosome research market.
• Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the exosome research market.